Truist Securities Reiterates Buy Rating on Vericel Corporation (VCEL)

Market Context

Vericel Corporation operates in the Healthcare sector. The stock currently trades at $47.81 with a market capitalization of $1.9B.

Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vericel Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Vericel Corporation

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Truist Securities	Buy	N/A
May 08, 2026	HC Wainwright & Co.	Buy	N/A
Apr 15, 2026	Truist Securities	Buy	N/A
Feb 27, 2026	HC Wainwright & Co.	Buy	N/A
Dec 18, 2025	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View VCEL Stock Page